Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin J D, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll H-J, Sobrero A, Tabernero J, van de Velde C
Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium.
Ann Oncol. 2009 Jun;20 Suppl 7:vii1-vii6. doi: 10.1093/annonc/mdp281.
This article summarizes the expert discussion on the management of hepatocellular carcinoma (HCC), which took place during the 10th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, June 2008. A multidisciplinary approach to a patient with HCC is essential, to guarantee optimal diagnosis and staging, planning of surgical options and selection of embolisation strategies or systemic therapies. In many patients, the underlying cirrhosis represents a challenge and determines therapeutic options. There is now robust evidence in favour of systemic therapy with sorafenib in patients with advanced HCC with preserved liver function. Those involved in the care for patients with HCC should be encouraged to participate in well-designed clinical trials, to increase evidence-based knowledge and to make further progress.
本文总结了2008年6月在巴塞罗那举行的第10届世界胃肠道癌症大会（WGICC）期间关于肝细胞癌（HCC）管理的专家讨论。对HCC患者采用多学科方法至关重要，以确保最佳诊断和分期、手术方案规划以及栓塞策略或全身治疗的选择。在许多患者中，潜在的肝硬化是一项挑战，并决定了治疗方案。目前有充分证据支持对肝功能良好的晚期HCC患者采用索拉非尼进行全身治疗。应鼓励参与HCC患者护理的人员参与精心设计的临床试验，以增加循证知识并取得进一步进展。
